<DOC>
	<DOCNO>NCT00003266</DOCNO>
	<brief_summary>RATIONALE : Methylphenidate may relieve side effect chemotherapy patient melanoma . It know whether receive methylphenidate effective receive therapy treat patient melanoma . PURPOSE : Randomized phase III trial determine methylphenidate effective therapy relief fatigue drowsiness treat patient melanoma receive high-dose interferon alfa 8-24 week .</brief_summary>
	<brief_title>Methylphenidate Treating Patients With Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether methylphenidate decrease fatigue lethargy cancer patient receive interferon alfa . II . Determine whether use methylphenidate patient population decrease number dose reduction interferon alfa due toxicity myelosuppression elevate liver function test . III . Assess whether efficacy toxicity methylphenidate patient population concentration dependent . IV . Compare fatigue subscale propose Brief Fatigue Inventory . OUTLINE : This randomize , double-blind , placebo-controlled , two arm study . Patients stratify accord initial fatigue level ( high v moderate ) , treatment tumor vaccine ( yes v ) . Patients randomize one two treatment arm . Arm I : Patients receive oral methylphenidate twice daily . Arm II : Patients receive oral placebo twice daily . Treatment continue 21 consecutive day dose escalation tolerate needed patient judgement , follow additional week evaluate effect drug withdrawal . Patients contact telephone least twice weekly 21 day treatment 7 day washout phase assess adverse rebound effect . Before study begin weekly clinic visit 4 week study period , patient complete series questionnaire measure mood , level fatigue lethargy , sense well . Patients also keep short daily diary study medication dose degree tiredness . Patients follow every 3 month 2 year , every 6 month next 3 year , annually thereafter . PROJECTED ACCRUAL : A total 200 patient accrue study within 39 month .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : On interferon alfa2b treatment least 8 week Dose must stable 2 week prior study Fatigue level least 4 Symptom Fatigue Self Evaluation Form ( 0 none , 10 bad possible ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : More 4 week Hematopoietic : Hematocrit least 30 % Hepatic : Not specify Renal : Creatinine great 2.0 mg/dL Other : No history follow : Chronic use anticonvulsant Seizure disorder Motor tic Glaucoma Family history diagnosis Tourette 's disorder No allergic reaction hypersensitivity methylphenidate Cognitively able participate Not incarcerate Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No monoamine oxidase inhibitor within 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>fatigue</keyword>
</DOC>